[1]
Parkash V, Fadare O, Tornos C, McCluggage WG. Committee Opinion No. 631: Endometrial Intraepithelial Neoplasia. Obstetrics and gynecology. 2015 Oct:126(4):897. doi: 10.1097/AOG.0000000000001071. Epub
[PubMed PMID: 26393443]
Level 3 (low-level) evidence
[2]
Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2000 Mar:13(3):295-308
[PubMed PMID: 10757340]
[3]
van der Meer AC, Hanna LS. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia. Clinical obesity. 2017 Feb:7(1):54-57. doi: 10.1111/cob.12168. Epub 2016 Dec 16
[PubMed PMID: 27984850]
Level 3 (low-level) evidence
[4]
Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. The Cochrane database of systematic reviews. 2012 Aug 15:2012(8):CD000402. doi: 10.1002/14651858.CD000402.pub4. Epub 2012 Aug 15
[PubMed PMID: 22895916]
Level 1 (high-level) evidence
[5]
Kaminski P, Bobrowska K, Pietrzak B, Bablok L, Wielgos M. Gynecological issues after organ transplantation. Neuro endocrinology letters. 2008 Dec:29(6):852-6
[PubMed PMID: 19112398]
Level 2 (mid-level) evidence
[6]
Bobrowska K, Kamiński P, Cyganek A, Pietrzak B, Jabiry-Zieniewicz Z, Durlik M, Paczek L. High rate of endometrial hyperplasia in renal transplanted women. Transplantation proceedings. 2006 Jan-Feb:38(1):177-9
[PubMed PMID: 16504696]
[7]
Niskakoski A, Pasanen A, Porkka N, Eldfors S, Lassus H, Renkonen-Sinisalo L, Kaur S, Mecklin JP, Bützow R, Peltomäki P. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. Gynecologic oncology. 2018 Jul:150(1):92-98. doi: 10.1016/j.ygyno.2018.04.566. Epub 2018 Apr 30
[PubMed PMID: 29716739]
[8]
Mills AM, Sloan EA, Thomas M, Modesitt SC, Stoler MH, Atkins KA, Moskaluk CA. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry. The American journal of surgical pathology. 2016 Feb:40(2):155-65. doi: 10.1097/PAS.0000000000000544. Epub
[PubMed PMID: 26523542]
[9]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018 Jan:68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4
[PubMed PMID: 29313949]
[10]
Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF, Weiss NS. Incidence of endometrial hyperplasia. American journal of obstetrics and gynecology. 2009 Jun:200(6):678.e1-6. doi: 10.1016/j.ajog.2009.02.032. Epub 2009 Apr 23
[PubMed PMID: 19393600]
[11]
Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. The Cochrane database of systematic reviews. 2004:(3):CD000402
[PubMed PMID: 15266429]
Level 1 (high-level) evidence
[12]
. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996 Feb 7:275(5):370-5
[PubMed PMID: 8569016]
[13]
Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM, Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003 Oct 1:290(13):1739-48
[PubMed PMID: 14519708]
Level 1 (high-level) evidence
[14]
Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985 Jul 15:56(2):403-12
[PubMed PMID: 4005805]
[15]
Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982 Jun 15:49(12):2547-59
[PubMed PMID: 7074572]
[16]
Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecologic oncology. 1994 Mar:52(3):373-8
[PubMed PMID: 8157194]
[17]
Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019 Apr:74(5):676-687. doi: 10.1111/his.13776. Epub 2019 Feb 10
[PubMed PMID: 30347477]
[18]
Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15:106(4):812-9
[PubMed PMID: 16400639]
[19]
Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L, Diener-West M, Kurman RJ. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. The American journal of surgical pathology. 1998 Aug:22(8):1012-9
[PubMed PMID: 9706982]
[20]
Emons G, Beckmann MW, Schmidt D, Mallmann P, Uterus commission of the Gynecological Oncology Working Group (AGO). New WHO Classification of Endometrial Hyperplasias. Geburtshilfe und Frauenheilkunde. 2015 Feb:75(2):135-136
[PubMed PMID: 25797956]
[21]
Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecologic oncology. 2000 Mar:76(3):287-90
[PubMed PMID: 10684697]
[22]
Salman MC, Usubutun A, Boynukalin K, Yuce K. Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia. Journal of gynecologic oncology. 2010 Jun:21(2):97-101. doi: 10.3802/jgo.2010.21.2.97. Epub 2010 Jun 30
[PubMed PMID: 20613899]
[23]
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2:497(7447):67-73. doi: 10.1038/nature12113. Epub
[PubMed PMID: 23636398]
[24]
Saccardi C, Vitagliano A, Marchetti M, Lo Turco A, Tosatto S, Palumbo M, De Lorenzo LS, Vitale SG, Scioscia M, Noventa M. Endometrial Cancer Risk Prediction According to Indication of Diagnostic Hysteroscopy in Post-Menopausal Women. Diagnostics (Basel, Switzerland). 2020 Apr 27:10(5):. doi: 10.3390/diagnostics10050257. Epub 2020 Apr 27
[PubMed PMID: 32349386]
[25]
Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstetrics and gynecology. 2002 Apr:99(4):663-70
[PubMed PMID: 12039131]
[26]
Gupta JK, Chien PF, Voit D, Clark TJ, Khan KS. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta obstetricia et gynecologica Scandinavica. 2002 Sep:81(9):799-816
[PubMed PMID: 12225294]
Level 1 (high-level) evidence
[27]
Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, Brand R, Grady D. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4:280(17):1510-7
[PubMed PMID: 9809732]
[28]
Wolfman W, Leyland N, Heywood M, Singh SS, Rittenberg DA, Soucy R, Allaire C, Awadalla A, Best C, Dunn S, Leroux N, Potestio F, Senikas V, Wallace S, Menzies R, Society of Obstetricians and Gynaecologists of Canada. Asymptomatic endometrial thickening. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2010 Oct:32(10):990-9
[PubMed PMID: 21176311]
[29]
. ACOG Committee Opinion No. 440: The Role of Transvaginal Ultrasonography in the Evaluation of Postmenopausal Bleeding. Obstetrics and gynecology. 2009 Aug:114(2 Pt 1):409-411. doi: 10.1097/AOG.0b013e3181b48feb. Epub
[PubMed PMID: 19623006]
Level 3 (low-level) evidence
[30]
Suh-Burgmann E, Hung YY, Armstrong MA. Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstetrics and gynecology. 2009 Sep:114(3):523-529. doi: 10.1097/AOG.0b013e3181b190d5. Epub
[PubMed PMID: 19701030]
[31]
Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta obstetricia et gynecologica Scandinavica. 2001 Sep:80(9):784-93
[PubMed PMID: 11531627]
[32]
Ben-Baruch G, Seidman DS, Schiff E, Moran O, Menczer J. Outpatient endometrial sampling with the Pipelle curette. Gynecologic and obstetric investigation. 1994:37(4):260-2
[PubMed PMID: 8050731]
[33]
Bedner R, Rzepka-Górska I. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. European journal of gynaecological oncology. 2007:28(5):400-2
[PubMed PMID: 17966221]
Level 2 (mid-level) evidence
[34]
Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima A, Noda K, Okada H, Kato J, Yakushiji M, Tanizawa O, Fujimoto S, Nozawa S, Takahashi T, Hasumi K, Furuhashi N, Aono T, Sakamoto A, Furusato M. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. The journal of obstetrics and gynaecology research. 1997 Jun:23(3):223-30
[PubMed PMID: 9255033]
[35]
Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. American journal of obstetrics and gynecology. 2010 Dec:203(6):547.e1-10. doi: 10.1016/j.ajog.2010.07.037. Epub
[PubMed PMID: 20934679]
Level 1 (high-level) evidence
[36]
Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. American journal of obstetrics and gynecology. 2015 Oct:213(4):469-78. doi: 10.1016/j.ajog.2015.03.037. Epub 2015 Mar 19
[PubMed PMID: 25797236]
Level 1 (high-level) evidence
[37]
Gallos ID, Ofinran O, Shehmar M, Coomarasamy A, Gupta JK. Current management of endometrial hyperplasia-a survey of United Kingdom consultant gynaecologists. European journal of obstetrics, gynecology, and reproductive biology. 2011 Oct:158(2):305-7. doi: 10.1016/j.ejogrb.2011.05.010. Epub 2011 Jun 12
[PubMed PMID: 21658836]
Level 3 (low-level) evidence
[38]
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute. 2005 Nov 16:97(22):1652-62
[PubMed PMID: 16288118]
[39]
Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, Richesson DA, Chatterjee N, Langholz B. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Feb 10:28(5):788-92. doi: 10.1200/JCO.2009.24.1315. Epub 2010 Jan 11
[PubMed PMID: 20065186]